Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
5.75-0.07 (-1.20%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Performance Outlook
Previous Close5.82
Open5.67
Bid2.32 x 1000
Ask6.11 x 1100
Day's Range5.67 - 5.94
52 Week Range5.25 - 15.78
Volume2,177
Avg. Volume26,564
Market Cap235.023M
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-1.33
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inventiva S.A. - American Depos
    ITOS: Rating decreased to a HOLDITEOS THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022

    Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape by Dr. Stephen HarrisonPresentation by Dr. Michael Cooreman of three scientific abstracts from NATIVE selected for poster presentations at the EASL International Liver Congress™ 2022 Update on LEGEND, Inventiva’s Phase IIa combination study with lanifibranor and SGLT2 inhibitor empagliflozin in pati

  • Zacks

    Here's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher

    Inventiva S.A. Sponsored ADR (IVA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

  • GlobeNewswire

    Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022

    Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the reduction of the FastTM score in association with the beneficial effects of lanifibranor on liver histology and biologically relevant biomarkers, in patients with NASH and F2/F3 fibrosis.the identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with lanifibran

Advertisement
Advertisement